European price cuts are taking an even bigger bite out of GlaxoSmithKline's ($GSK) sales than CEO Andrew Witty had expected--and he expected a sizable one. Report
European price cuts are taking an even bigger bite out of GlaxoSmithKline's ($GSK) sales than CEO Andrew Witty had expected--and he expected a sizable one. Report